Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India

A Phase 1, Open-Label, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-111F + MPL-SE Vaccine (Recombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE) in Healthy Adults In India

The purpose of this study is to determine if a vaccine (called Leish-111f + MPL-SE) is safe and whether it can or cannot produce a protective response against visceral leishmaniasis when injected to healthy subjects.

Study Overview

• Status: Completed
• Conditions: Visceral Leishmaniasis; Post-kala-azar Dermal Leishmaniasis
• Intervention / Treatment: Biological: Leish-111f + MPL-SE Adjuvant

Detailed Description

The purpose of this study is to determine the safety, tolerability, and immunogenicity of an investigational vaccine being developed for immunotherapy of visceral leishmaniasis (VL) and post kala-azar dermal leishmaniasis (PKDL). The vaccine, identified as Leish-111f + MPL-SE, consists of a recombinant three-antigen Leishmania polyprotein (Leish-111f) together with adjuvant MPL-SE.

The primary objective is to evaluate the safety and tolerability of the Leish-111f + MPL-SE vaccine given as three subcutaneous injections every 28 days at each of three dose levels of the Leish-111f protein (5 μg, 10 μg, or 20 μg) together with MPL-SE adjuvant (25 μg) in healthy adults.

The secondary objective is to assess the immunogenicity of the vaccine by evaluating T-cell and antibody response to the Leish-111f protein of the vaccine.

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 1

Contacts and Locations

Study Locations

• India
  • Uttar Pradesh
    • Varanasi, Uttar Pradesh, India, 221 005
      • Banaras Hindu University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 54 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males and females ≥ 18 years and < 55 years of age.
• Must be in good general health as confirmed by a medical history and physical exam.
• DAT titer must be <1:400 and rK39 serology negative (for inclusion in the DAT-negative group) or DAT titer ≥1:1600 (for inclusion in the DAT-positive group).
• The following laboratory blood tests must have values within the normal ranges at screening (Appendix 4): sodium, potassium, urea, ALT, AST, total bilirubin, creatinine, alkaline phosphatase, glucose, hemoglobin, total WBC count and platelet count.
• The following serology tests must be negative at screening: HIV 1/2, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody. All subjects will receive HIV related counseling prior to testing. Subjects with positive HIV test results will receive counseling at the University and will be referred to the national AIDS control program for treatment if appropriate.
• Subjects must give written informed consent, be willing and able to attend all required visits, have a permanent address, and be reachable by study site personnel.
• Female subjects of childbearing potential must have a negative urine pregnancy test at screening, a negative urine pregnancy test within 24 hours before study injection, must not be breast-feeding, and are required to use adequate contraception through Day 84 of the study. These precautions are necessary due to unknown effects that Leish-111f + MPL-SE might have in a fetus or newborn infant.

Exclusion Criteria:

• Previous exposure to Leishmania vaccines or experimental products containing MPL-SE.
• Participation in another experimental protocol or receipt of any investigational products within 30 days prior to the first administration of study injection.
• Known use of injected or oral corticosteroids within 6 weeks prior to the first administration of study injection.
• History of autoimmune disease or other causes of immunosuppressive states.
• History or evidence of any acute or chronic illness that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or the immunogenicity of the vaccine. (Potential subjects presenting with concomitant illness will be referred for clinical care.)
• History of use of any medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or the immunogenicity of the vaccine.
• History of significant psychiatric illness.
• Known to be a current drug or alcohol abuser.
• Subjects with a history of previous anaphylaxis, severe allergic reaction to vaccines or unknown allergens, or allergic reaction to eggs.
• History of chronic headaches or migraine.
• Subjects who are unlikely to cooperate with the requirements of the study protocol.
• Subjects who are not permanent residents or who are planning to move to another town/city.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Low dose; Biological/Vaccine: Leish-111f + MPL-SE Adjuvant	Biological: Leish-111f + MPL-SE Adjuvant
Experimental: Medium dose; Biological/Vaccine: Leish-111f + MPL-SE Adjuvant	Biological: Leish-111f + MPL-SE Adjuvant
Experimental: High dose; Biological/Vaccine: Leish-111f + MPL-SE Adjuvant	Biological: Leish-111f + MPL-SE Adjuvant

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Injection site reactions	For 7 days following each injection.

Collaborators and Investigators

• Sponsor: IDRI
• Collaborators: Bill and Melinda Gates Foundation
• Investigators: Principal Investigator: Shyam Sundar, MD, Banaras Hindu University

Study record dates

Study Major Dates

• Study Start: April 1, 2007
• Primary Completion (Actual): November 1, 2008
• Study Completion (Actual): November 1, 2008

Study Registration Dates

• First Submitted: June 12, 2007
• First Submitted That Met QC Criteria: June 12, 2007
• First Posted (Estimate): June 14, 2007

Study Record Updates

• Last Update Posted (Estimate): April 3, 2015
• Last Update Submitted That Met QC Criteria: April 1, 2015
• Last Verified: April 1, 2015

More Information

Terms related to this study

• Keywords: vaccine; visceral leishmaniasis
• Additional Relevant MeSH Terms: Skin Diseases; Infections; Vector Borne Diseases; Parasitic Diseases; Protozoan Infections; Skin Diseases, Parasitic; Skin Diseases, Infectious; Euglenozoa Infections; Leishmaniasis; Leishmaniasis, Visceral
• Other Study ID Numbers: IDRI-LVVPX-104